Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 644

1.

In vitro and in vivo antitumor activity of a novel pH-activated polymeric drug delivery system for doxorubicin.

Huan M, Zhang B, Teng Z, Cui H, Wang J, Liu X, Xia H, Zhou S, Mei Q.

PLoS One. 2012;7(9):e44116. doi: 10.1371/journal.pone.0044116. Epub 2012 Sep 24.

2.

The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin.

Xiong XB, Ma Z, Lai R, Lavasanifar A.

Biomaterials. 2010 Feb;31(4):757-68. doi: 10.1016/j.biomaterials.2009.09.080. Epub 2009 Oct 8. Erratum in: Biomaterials. 2011 Jun;32(17):4194. Dosage error in article text.

PMID:
19818492
3.

Synthesis of doxorubicin α-linolenic acid conjugate and evaluation of its antitumor activity.

Liang CH, Ye WL, Zhu CL, Na R, Cheng Y, Cui H, Liu DZ, Yang ZF, Zhou SY.

Mol Pharm. 2014 May 5;11(5):1378-90. doi: 10.1021/mp4004139. Epub 2014 Apr 10.

PMID:
24720787
4.

pH triggered doxorubicin delivery of PEGylated glycolipid conjugate micelles for tumor targeting therapy.

Hu FQ, Zhang YY, You J, Yuan H, Du YZ.

Mol Pharm. 2012 Sep 4;9(9):2469-78. doi: 10.1021/mp300002v. Epub 2012 Aug 7.

PMID:
22827551
5.

Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery.

Prabaharan M, Grailer JJ, Pilla S, Steeber DA, Gong S.

Biomaterials. 2009 Oct;30(29):5757-66. doi: 10.1016/j.biomaterials.2009.07.020. Epub 2009 Jul 29.

PMID:
19643472
6.

Development and evaluation of pH-responsive single-walled carbon nanotube-doxorubicin complexes in cancer cells.

Gu YJ, Cheng J, Jin J, Cheng SH, Wong WT.

Int J Nanomedicine. 2011;6:2889-98. doi: 10.2147/IJN.S25162. Epub 2011 Nov 17.

7.

PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.

Veronese FM, Schiavon O, Pasut G, Mendichi R, Andersson L, Tsirk A, Ford J, Wu G, Kneller S, Davies J, Duncan R.

Bioconjug Chem. 2005 Jul-Aug;16(4):775-84.

PMID:
16029018
8.

Cellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticles.

Ye WL, Du JB, Zhang BL, Na R, Song YF, Mei QB, Zhao MG, Zhou SY.

PLoS One. 2014 May 14;9(5):e97358. doi: 10.1371/journal.pone.0097358. eCollection 2014.

9.

Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer.

Ye WL, Zhao YP, Li HQ, Na R, Li F, Mei QB, Zhao MG, Zhou SY.

Sci Rep. 2015 Sep 30;5:14614. doi: 10.1038/srep14614.

10.

Dual subcellular compartment delivery of doxorubicin to overcome drug resistant and enhance antitumor activity.

Song YF, Liu DZ, Cheng Y, Liu M, Ye WL, Zhang BL, Liu XY, Zhou SY.

Sci Rep. 2015 Nov 4;5:16125. doi: 10.1038/srep16125.

11.

Comparative studies of polyethylenimine-doxorubicin conjugates with pH-sensitive and pH-insensitive linkers.

Dong DW, Tong SW, Qi XR.

J Biomed Mater Res A. 2013 May;101(5):1336-44. doi: 10.1002/jbm.a.34450. Epub 2012 Oct 15.

PMID:
23065848
12.

Deposition of doxorubicin in rats following administration of three newly synthesized doxorubicin conjugates.

Huan M, Tian S, Cui H, Zhang B, Su D, Wang J, Li K, Cao W.

Biomed Res Int. 2013;2013:926584. doi: 10.1155/2013/926584. Epub 2013 Dec 5.

13.

A novel delivery system of doxorubicin with high load and pH-responsive release from the nanoparticles of poly (α,β-aspartic acid) derivative.

Wang X, Wu G, Lu C, Zhao W, Wang Y, Fan Y, Gao H, Ma J.

Eur J Pharm Sci. 2012 Aug 30;47(1):256-64. doi: 10.1016/j.ejps.2012.04.007. Epub 2012 Apr 13.

PMID:
22522116
14.

Stimuli-responsive PEGylated prodrugs for targeted doxorubicin delivery.

Xu M, Qian J, Liu X, Liu T, Wang H.

Mater Sci Eng C Mater Biol Appl. 2015 May;50:341-7. doi: 10.1016/j.msec.2015.01.098. Epub 2015 Jan 31.

PMID:
25746279
15.

Design, synthesis and evaluation of N-acetyl glucosamine (NAG)-PEG-doxorubicin targeted conjugates for anticancer delivery.

Pawar SK, Badhwar AJ, Kharas F, Khandare JJ, Vavia PR.

Int J Pharm. 2012 Oct 15;436(1-2):183-93. doi: 10.1016/j.ijpharm.2012.05.078. Epub 2012 Jun 18.

PMID:
22721850
16.

Photothermal-chemotherapy with doxorubicin-loaded hollow gold nanospheres: A platform for near-infrared light-trigged drug release.

You J, Zhang R, Zhang G, Zhong M, Liu Y, Van Pelt CS, Liang D, Wei W, Sood AK, Li C.

J Control Release. 2012 Mar 10;158(2):319-28. doi: 10.1016/j.jconrel.2011.10.028. Epub 2011 Oct 28.

17.

Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.

Zhou X, Zhang M, Yung B, Li H, Zhou C, Lee LJ, Lee RJ.

Int J Nanomedicine. 2012;7:5465-74. doi: 10.2147/IJN.S33965. Epub 2012 Oct 16.

18.

Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.

Han L, Huang R, Liu S, Huang S, Jiang C.

Mol Pharm. 2010 Dec 6;7(6):2156-65. doi: 10.1021/mp100185f. Epub 2010 Oct 14.

PMID:
20857964
19.

Tumor-preferential sustained drug release enhances antitumor activity of block copolymer micelles.

Ponta A, Bae Y.

J Drug Target. 2014 Aug;22(7):619-28. doi: 10.3109/1061186X.2014.910793. Epub 2014 Apr 28.

PMID:
24766185
20.

Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery.

Scomparin A, Salmaso S, Bersani S, Satchi-Fainaro R, Caliceti P.

Eur J Pharm Sci. 2011 Apr 18;42(5):547-58. doi: 10.1016/j.ejps.2011.02.012. Epub 2011 Mar 1.

PMID:
21371555
Items per page

Supplemental Content

Write to the Help Desk